Previous studies of serological biomarkers for the prediction of outcomes in individuals with COPD have mainly focused on the systemic inflammatory response by evaluating biomarkers such as interleukin-6, CRP and fibrinogen. This evidence concerns the gene IL6 and chronic obstructive pulmonary disease.